OncoMatch/Clinical Trials/NCT05394103
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Is NCT05394103 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Q901 and KEYTRUDA® (pembrolizumab) for advanced cancer.
Treatment: Q901 · KEYTRUDA® (pembrolizumab) — Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Cardiac function
New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months excluded; QTcF >470 msec (females) and >450 msec (males) excluded
New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months; Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec (females) and >450 msec (males)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Phoenix, Arizona
- University of Southern California · Los Angeles, California
- Mayo Clinic · Jacksonville, Florida
- Northwestern University · Chicago, Illinois
- Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify